How does the FDA’s expanded Padcev-Keytruda approval affect AstraZeneca’s bladder cancer strategy?

The FDA’s move to broaden Padcev and Keytruda’s use in bladder cancer strengthens the combo’s role as a core treatment in urothelial carcinoma. This shift pressures AstraZeneca to differentiate its pipeline or move earlier in therapy lines, as the expanded approval reshapes competition and payer dynamics in oncology.